, a head in developing state-of-the-art, minimally invasive surgical products, december 31 announced its financial outcomes for the fourth quarter and year ended, 2012. FOURTH QUARTER 2012 SUMMARY Total income of $96.9 million. Income from procedures of $15.1 million, or operating margin of 15.6 %. Net income relevant to common stockholders of $10.3 million, or $0.30 per diluted share. FULL YEAR 2012 SUMMARY Total revenue of $368.5 million. Income from procedures of $64.1 million, or operating margin of 17.4 %. Net income relevant to common stockholders of $42.8 million, or $1.25 per diluted share. Income – FOURTH QUARTER Total income for the fourth quarter of 2012 was $96.9 million, compared to $92.4 million for the fourth quarter of 2011, an increase of 4.9 %. Revenue for the fourth one fourth of 2012 were $92.2 million in comparison to $88.5 million in the fourth quarter of 2011, a rise of 4.3 %.Related StoriesFDA grants accelerated approval for Tagrisso to treat patients with advanced NSCLCSausages With Antioxidants From Berries TO AVOID CancerCornell biomedical engineers develop 'super organic killer cells' to destroy malignancy cells in lymph nodesThey also discovered that to be normally expressed in the cell membrane instead, claudin-1 was located in the cancer of the colon cell nucleus and cytoplasm instead. Those cancer cells that metastasized from the principal tumor site were discovered expressing the highest degrees of claudin-1 and also exhibited a greater degree of claudin-1 mislocalization.